title: [Psoriasis and mud bath therapy: clinical-experimental study].
abstract: OBJECTIVE
  The psoriasis is chronic disease characterized from an acceleration of the kinetic of the cells of epidermis. To front of the empirical evidence of the benefits of the thermal therapy in the psoriasis, the experimentals-clinics studies is insufficient. The aim of research it has been that of quantify the benefits of the mud-bath therapy with mineral water in the psoriasis.
  
  
  METHODS
  The study has been channel on a champion of 30 subjects of which 19 of male sex and 11 of female sex with middle equal age to 56 years +/- 5.3 affected from psoriasis. The subjects of the examined champion have been divided to random in 2 groups: A and B. The group A has been treated with drugs used for psoriasis for 12 days; the B group has been treated, always for 12 consecutive days, with mud-bath therapy (FBT) with mineral water obtained from the mineral sources (chlorinate-sulphureous-bicarbonate) of the Spa of Stabia in Castellammare (NA). To the beginning and at the end of the advised treatments has been valued the prurient symptomatology and the PASI (Psoriasis and Severity Index).
  
  
  RESULTS
  The data highlight an significant (P < 0.05) reduction is of the prurient symptomatology and of the PASI in both the groups considered.
  
  
  CONCLUSIONS
  The results of this first step of investigations seems to highlight that the FBT treatment, to the same way of the drugs anti-psoriasis, results useful in the ameliorate the quality of life of these patients.
authors.affiliation: Seconda Università degli Studi di Napoli, Crisceb (Centro di Ricerche Interdipartimentali, Scienze Computazionali e Biotecnologiche), Scuola di Specializzazione in Idrologia Medica, Napoli, Italia. maria.costantino@unina2.it
authors.forename: M
authors.initials: M
authors.lastname: Costantino
authors.forename: E
authors.initials: E
authors.lastname: Lampa
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002990:Clobetasol / Q000008:administration & dosage / Q000627:therapeutic use; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003899:Desoximetasone / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D008900:Mineral Waters / Q000627:therapeutic use; D000068656:Mometasone Furoate; D009094:Mud Therapy; D009824:Ointments; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D011788:Quality of Life; D012176:Retinoids / Q000008:administration & dosage / Q000627:therapeutic use; D012494:Sampling Studies; D013997:Time Factors; D016896:Treatment Outcome; D014807:Vitamin D / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D005938:Glucocorticoids; D008900:Mineral Waters; D009824:Ointments; D011244:Pregnadienediols; D012176:Retinoids; D000068656:Mometasone Furoate; D014807:Vitamin D; D003899:Desoximetasone; D016572:Cyclosporine; D002990:Clobetasol